# The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain "BETA"

> **NCT05544656** · PHASE3 · UNKNOWN · sponsor: **Semmelweis University** · enrollment: 150 (estimated)

## Conditions studied

- Low Back Pain

## Interventions

- **DRUG:** Tolperisone Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05544656
- **Lead sponsor:** Semmelweis University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-13
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544656, "The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain "BETA"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05544656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*